Povidone-iodine 2% Eye Drop Versus Artificial Tear Drop for Treatment of Adenoviral Keratoconjunctivitis
1 other identifier
interventional
200
0 countries
N/A
Brief Summary
Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started Aug 2019
Shorter than P25 for phase_1
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 24, 2019
CompletedFirst Posted
Study publicly available on registry
August 1, 2019
CompletedStudy Start
First participant enrolled
August 23, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 22, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
November 22, 2019
CompletedAugust 1, 2019
July 1, 2019
2 months
July 24, 2019
July 30, 2019
Conditions
Outcome Measures
Primary Outcomes (2)
Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
Decreased patient's symptoms
3 months
Povidone-iodine 2% eye drop
Decreased viral load based on PCR results
3 months
Study Arms (2)
EKC patients
ACTIVE COMPARATORPovidone-iodine 2% eye drop will be prescribed four times a day All patients will learn how to improve the hygiene level in order to reduce transmission
Control group
NO INTERVENTIONAll patients will undergo observational treatments including artificial tear drop and improving hygiene level
Interventions
Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
Eligibility Criteria
You may qualify if:
- Patients suspected for viral conjunctivitis
You may not qualify if:
- Allergic to iodized materials
- Age under 17
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate professor of ophthalmology
Study Record Dates
First Submitted
July 24, 2019
First Posted
August 1, 2019
Study Start
August 23, 2019
Primary Completion
October 22, 2019
Study Completion
November 22, 2019
Last Updated
August 1, 2019
Record last verified: 2019-07